Can I get retatrutide now with a prescription?

No. Retatrutide is investigational. It is not approved by the FDA for any indication, no licensed pharmacy dispenses it, and no U.S. prescriber can legally prescribe it outside a clinical trial. Products sold online as 'research peptide' retatrutide are outside the regulated supply chain, and their identity, purity, dose, and sterility are unverified.

How much weight did people lose on retatrutide in Phase 3?

In TRIUMPH-1, announced May 21, 2026, adults with obesity or overweight and at least one weight-related condition but without diabetes lost an average of 19.0% on 4 mg, 25.9% on 9 mg, and 28.3% (70.3 lbs) on 12 mg at 80 weeks, versus 2.2% on placebo. In a 104-week extension of participants with a starting BMI of 35 or higher, the 12 mg group averaged 30.3% (85.0 lbs).

How is retatrutide different from Ozempic and Mounjaro?

Semaglutide (Ozempic, Wegovy) acts on one receptor, GLP-1. Tirzepatide (Mounjaro, Zepbound) acts on two, GIP and GLP-1. Retatrutide acts on three: GIP, GLP-1, and glucagon. The glucagon receptor is the addition, and it is thought to raise energy expenditure and reduce liver fat in ways the dual agonists do not.

What could delay retatrutide's approval?

Several things. Lilly has not yet reported all Phase 3 readouts, and a filing depends on the full data package. The FDA can extend a review by three months if it deems a submission a major amendment. Manufacturing capacity and inspection findings can also affect timing. Finally, a stated filing plan is a plan, not a commitment, and pharmaceutical timelines slip routinely.

When Will Retatrutide Be FDA Approved?

Q: When will retatrutide be FDA approved?

No approval date exists yet, because Lilly has not filed the application. In its July 23, 2026 announcement of the TRIUMPH-2 and TRIUMPH-3 results, Lilly stated that it plans to submit a Biologics License Application for retatrutide to the FDA in Q1 2027. Under standard FDA review timelines, a decision would follow roughly 12 months after submission, which places the earliest realistic action date in 2028. A priority review designation would shorten that to roughly 8 months.

The short answer: there is no approval date yet, because the application has not been filed. Eli Lilly stated on July 23, 2026 that it plans to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027. Under standard FDA review timelines, that puts the earliest realistic decision somewhere in 2028. A priority review would pull it earlier, into late 2027. Anyone telling you retatrutide is available now is not selling you an approved drug.

Here is where the program actually stands, readout by readout, and what has to happen between now and a decision.

What has Lilly actually said about filing?

One sentence, and it is the only official timeline statement that exists. In the July 23, 2026 press release announcing topline results from two additional Phase 3 trials, Lilly wrote that it "plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027" (Eli Lilly and Company, July 23, 2026).

That is a plan, not a filed application, and not a commitment. Pharmaceutical filing timelines move.

How long does FDA review take after filing?

The agency works to performance goals set under the Prescription Drug User Fee Act. For a new molecular entity, the FDA takes roughly 60 days to decide whether to accept the application for review. The review clock then runs from that filing date:

Standard review: a goal of 10 months from the filing date, which is about 12 months from submission.
Priority review: a goal of 6 months from the filing date, which is about 8 months from submission.

Applying those to a Q1 2027 submission gives a rough window of late 2027 under priority review and the first half of 2028 under standard review. The FDA can also extend a review by three months if it classifies new information as a major amendment. Details on the review pathways are published by the FDA.

What did TRIUMPH-1 show?

TRIUMPH-1 was the first registrational Phase 3 obesity trial, and Lilly announced topline results on May 21, 2026. It randomized 2,339 adults with obesity, or overweight plus at least one weight-related condition, and without type 2 diabetes, to retatrutide 4 mg, 9 mg, 12 mg, or placebo (Eli Lilly, May 21, 2026).

Average weight loss at 80 weeks:

4 mg: 19.0% (47.2 lbs)
9 mg: 25.9% (64.4 lbs)
12 mg: 28.3% (70.3 lbs)
Placebo: 2.2% (5.5 lbs)

In a 104-week extension of 532 participants who started with a BMI of 35 or higher, the 12 mg group averaged 30.3% (85.0 lbs). Nearly half of the 12 mg group, 45.3%, lost at least 30% of body weight, compared with 0.5% on placebo.

The tolerability picture was consistent with the drug class and dose-dependent. Nausea occurred in 28.6%, 38.4%, and 42.4% of the 4 mg, 9 mg, and 12 mg groups versus 14.8% on placebo. Diarrhea occurred in 25.2%, 34.1%, and 32.0% versus 13.5%. Discontinuation due to adverse events was 4.1%, 6.9%, and 11.3% versus 4.9% on placebo.

What did TRIUMPH-2 and TRIUMPH-3 show?

Both reported topline on July 23, 2026, and both matter for the filing because they extend the drug beyond the simplest population.

TRIUMPH-2: adults with type 2 diabetes and obesity or overweight

At 80 weeks, average weight loss was 12.7% (29.8 lbs) on 4 mg, 19.1% (45.4 lbs) on 9 mg, and 20.8% (49.6 lbs) on 12 mg, versus 4.0% (9.3 lbs) on placebo. A1C fell by an average of up to 1.6 percentage points, versus 0.2 on placebo. Discontinuation due to adverse events was 3.8%, 11.6%, and 7.7% across the three doses versus 4.9% on placebo.

Weight loss is consistently smaller in people with type 2 diabetes across this entire drug class, so the drop from roughly 28% to roughly 21% at the top dose is expected rather than surprising.

TRIUMPH-3: adults with severe obesity and established cardiovascular disease

At 80 weeks, average weight loss was 21.6% (52.7 lbs) on 9 mg and 22.6% (55.8 lbs) on 12 mg, versus 3.2% (7.7 lbs) on placebo. Discontinuation due to adverse events was 9.8% and 13.5% versus 4.8% on placebo.

Note what TRIUMPH-3 is and is not. It measured weight in people who already have cardiovascular disease. It was not designed to show that retatrutide prevents heart attacks or strokes. That is a separate and much longer kind of trial, and semaglutide's SELECT trial is the template for it.

What still has to happen before a filing?

A BLA is a complete data package, not a single trial. Several things sit between today and a Q1 2027 submission:

Remaining Phase 3 readouts. The TRIUMPH program covers additional populations and indications, and Lilly has continued to report them through 2026. Our tracker of retatrutide clinical trials in 2026 follows each one.
Full safety database. Regulators want pooled adverse event data across the whole program, not per-trial topline summaries. The dose-dependent discontinuation rates in TRIUMPH-1 and TRIUMPH-3 are the kind of detail that gets scrutinized closely.
Manufacturing. Chemistry, manufacturing, and controls data plus facility readiness are routine sources of delay for injectable products, and the GLP-1 class has strained supply repeatedly.
Peer-reviewed publication. Topline press releases are summaries. Full results with confidence intervals and prespecified analyses are what the field will judge, and most of these have not yet been published in full.

Why you should not buy "research peptide" retatrutide

Because retatrutide has no approval, an entire gray market has grown around it, usually labeled "for research use only, not for human consumption." That label is a legal shield, not a quality statement.

These products sit outside the regulated supply chain. Nobody has verified the identity of the molecule, the actual dose in the vial, the purity, or the sterility. The FDA has issued repeated warnings about counterfeit and unapproved products in this drug class, including specific alerts about unapproved GLP-1 products sold for weight loss and dosing errors that sent people to emergency departments.

There is also a straightforward clinical point. The doses used in TRIUMPH-1 were reached through a structured escalation schedule under medical supervision, with a discontinuation rate above 11% at the top dose even in that setting. Self-administering an unverified compound at a guessed dose is not the same experiment.

If you want a triple-agonist-adjacent option that is actually approved and prescribable today, the dual agonist tirzepatide is covered in depth at mounjaro.md, and our comparison of retatrutide versus tirzepatide lays out what the third receptor actually adds.

The bottom line

Retatrutide is not approved, and the only official timeline is Lilly's stated plan to file a BLA in Q1 2027. Standard FDA review math puts a decision in 2028, with priority review as the faster case in late 2027. The Phase 3 efficacy results released so far are the strongest weight loss numbers reported for any obesity drug, topping out at 28.3% at 80 weeks and 30.3% at 104 weeks in TRIUMPH-1. The tolerability data is real too, and dose-dependent.

Watch for two things next: the remaining Phase 3 readouts, and the actual filing announcement. Until the FDA accepts an application, every projected launch date you read is arithmetic on a press release.

Last updated: August 2026. This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not approved by the FDA. Do not take unapproved or gray-market medications.